benzoxazoles has been researched along with Brain Stem Neoplasms, Primary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asnaghi, L; Eberhart, CG; Kambhampati, M; Kaur, H; Miyahara, H; Natsumeda, M; Nazarian, J; Raabe, EH; Rodgers, L; Rubens, JA; Taylor, IC; Warren, KE; Yadavilli, S | 1 |
1 other study(ies) available for benzoxazoles and Brain Stem Neoplasms, Primary
| Article | Year |
|---|---|
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
Topics: Animals; Apoptosis; Benzoxazoles; Brain Stem Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemoradiotherapy; Dose-Response Relationship, Drug; Glioma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Ribosomal Protein S6 Kinases; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |